Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR447971 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| SAR447971 | EXPERIMENTAL | Single or multiple doses by mouth as per protocol |
| Placebo | PLACEBO_COMPARATOR | Single or multiple doses by mouth as per protocol |
| Name | Type | Description |
|---|---|---|
| SAR447971 | DRUG | Pharmaceutical form: Tablet Route of administration: Oral |
| Placebo | DRUG | Pharmaceutical form: Tablet Route of administration: Oral |
Inclusion Criteria: For participation in SAD20411/MAD20412: * Male and/or female participant, between 18 and 55 years of age, inclusive at the time of signing the ICF. * Appearing healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). For part...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
SAR447971 is an investigational small molecule being developed for hidradenitis, a chronic inflammatory skin condition. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
SAR447971 targets CDK2, a protein involved in cell cycle regulation. By modulating CDK2 activity, the drug is being studied for its potential therapeutic effect in hidradenitis, though its exact mechanism in this condition is still under investigation.
SAR447971 is being developed by Kymera Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KYMR. The company is conducting a Phase 1 first-in-human study of the drug.
SAR447971 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is currently recruiting participants.
SAR447971 is being evaluated in a Phase 1 first-in-human study with the identifier NCT07629336. This randomized, double-blind, placebo-controlled trial is recruiting 114 participants with hidradenitis and healthy volunteers in the Netherlands.
SAR447971 is a distinct investigational small molecule developed by Kymera Therapeutics. It is not known to be the same as any other drug in the company's pipeline, and no alternative names for SAR447971 have been disclosed.